Health Trials

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

ConditionsClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Lung CarcinomaLocally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaMetastatic Lung CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1/PD-L1 treatment and others do not.

Eligibility criteria

Qualifiers

Are 18 years of age or older

Have histologic evidence of locally or regionally advanced or stage IV malignancy

Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)

Have an understanding of the protocol and its requirements, risks, and discomforts

Disqualifiers

Inability on the part of the patient to understand the informed consent or be compliant with the protocol

Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above)

Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Electronic Health Record Review

Treatment groups

500 Participants
are divided into 1 treatment group

Sponsors and collaborators

Mayo Clinic

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov